D.E. Shaw & Co
CLYM

D.E. Shaw & Co’s Climb Bio CLYM Stock Holding History

D.E. Shaw & Co’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Buy
+28,800
New +$297K ﹤0.01% 4320
2021
Q4 		– Sell
-14,912
Closed -$268K – 5767
2021
Q3 		$268K Buy
+14,912
New +$308K ﹤0.01% 4423

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co's CLYM Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Climb Bio (CLYM) in Q2 2026: 28,800 shares worth $376K. The stake represents ﹤0.01% of the portfolio and ranks #4320 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in CLYM as recently as Q3 2021.

D.E. Shaw & Co first reported a position in CLYM in Q3 2021 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • D.E. Shaw & Co held 28,800 shares of Climb Bio worth $376K as of Q2 2026.
  • Climb Bio was a new D.E. Shaw & Co position in Q2 2026.
  • Climb Bio made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4320 holding.
  • D.E. Shaw & Co first reported a position in Climb Bio in Q3 2021 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.